The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.

Abstract:

BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from a too narrow perspective' and (iv) 'The lack of well-described & standardized interventions'. This study aims to determine how healthcare providers and social workers experience and deal with these hurdles in practice and what solutions or new insights they would suggest. METHODS:Twenty-two professionals of welfare interventions carried out in Flanders, were interviewed about the four described hurdles using a semi-structured interview. A thematic framework was developed to enable the qualitative analysis. The analysis of the semi-structured interviews was facilitated through the use of the software program QRS NVivo 10. RESULTS:The interviews revealed a clear need to tackle these hurdles. The interviewees confirmed that further study of condition-specific outcomes in economic evaluations are needed, especially in the field of mental health and stress. The proposed dimensions for the condition-specific questionnaires varied however between the groups of interviewees (i.e. general practitioners vs social workers). With respect to QoL externalities, the interviewees confirmed that welfare interventions have an impact on the social environment of the patient (friends and family). There was however no consensus on how this impact of QoL externalities should be taken into account in welfare interventions. Professionals also suggested that besides health care costs, the impact of welfare interventions on work productivity, the patients' social life and other items should be incorporated. Standardization appears to be of limited added value for most of the interviewees because they need a certain degree of freedom to interpret the intervention. Furthermore, the target population of the interventions is diverse which requires a tailor-made approach. CONCLUSION:This qualitative research demonstrated that these hurdles occur in practice. The proposed solutions for these hurdles can contribute to the improvement of the methodological quality of economic evaluations of welfare interventions.

authors

Schepers J,Plaete J,De Bourdeaudhuij I,Annemans L,Simoens S

doi

10.1080/14737167.2017.1282316

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

421-429

issue

4

eissn

1473-7167

issn

1744-8379

journal_volume

17

pub_type

杂志文章
  • Health related quality of life impact from rotavirus diarrhea on children and their family caregivers in Thailand.

    abstract:BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,多中心研究

    doi:10.1080/14737167.2018.1386561

    authors: Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

    更新日期:2018-04-01 00:00:00

  • Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

    abstract:INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2019.1554437

    authors: Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

    更新日期:2019-04-01 00:00:00

  • Treatment switching in oncology trials and the acceptability of adjustment methods.

    abstract::Treatment switching has become an important issue in the development and approval of new drugs, particularly in oncology. Randomized controlled trials (RCTs) represent the gold standard for evaluating the effectiveness of interventions, but often patients randomized to the control group are permitted to switch onto th...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 社论

    doi:10.1586/14737167.2015.1037835

    authors: Latimer NR

    更新日期:2015-01-01 00:00:00

  • Application of electronic medical record data for health outcomes research: a review of recent literature.

    abstract::Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.13.7

    authors: Lin J,Jiao T,Biskupiak JE,McAdam-Marx C

    更新日期:2013-04-01 00:00:00

  • Cost-effective approaches to influenza prevention and treatment.

    abstract::Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.2.141

    authors: Rothberg M

    更新日期:2005-04-01 00:00:00

  • Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses.

    abstract:OBJECTIVES:To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). METHODS:Three systematic literature reviews were conducted in MEDLINE and Embase to capture all relevant publications reporting 1) the epidemiology of T2D and complications in T2D and 2) th...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1782748

    authors: Alzaid A,Ladrón de Guevara P,Beillat M,Lehner Martin V,Atanasov P

    更新日期:2020-07-20 00:00:00

  • Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis.

    abstract:AIM:To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS:This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.4.337

    authors: Roger A,Fortea J,Mora S,Artés M

    更新日期:2008-08-01 00:00:00

  • Trends in translation requests and arising issues regarding cultural adaptation.

    abstract::Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.27

    authors: Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

    更新日期:2011-06-01 00:00:00

  • Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.

    abstract:OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1411193

    authors: Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

    更新日期:2018-06-01 00:00:00

  • Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

    abstract:INTRODUCTION:During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2018.1485099

    authors: Vergnenègre A,Chouaïd C

    更新日期:2018-10-01 00:00:00

  • Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.

    abstract::Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.2.111

    authors: Gladman DD,Brown RE

    更新日期:2008-04-01 00:00:00

  • Promoting pan-European cancer research for the benefit of all cancer patients.

    abstract::The European Organisation for Research and Treatment of Cancer (EORTC) 50th Anniversary Conference was held on the 15-16 March in Brussels, Belgium. More than 1100 participants (including EORTC members and staff, national research organizations, health authorities, patient advocacy groups, European Commission, cancer ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1586/erp.12.32

    authors: Bean J,Bottomley A,Meunier F

    更新日期:2012-08-01 00:00:00

  • Global cost modeling analysis of HIV-1 and HCV viral load assays.

    abstract::This review addresses hidden costs associated with the Bayer VERSANT assay, Roche AMPLICOR MONITOR test and COBAS AMPLICOR MONITOR test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effectiv...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.4.383

    authors: Elbeik T,Chen YM,Soutchkov SV,Loftus RA,Beringer S

    更新日期:2003-08-01 00:00:00

  • Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.

    abstract:BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2019.1632194

    authors: Wijnen BFM,Thielen FW,Konings S,Feenstra T,Van Der Gaag M,Veling W,De Haan L,Ising H,Hiligsmann M,Evers SMAA,Smit F,Lokkerbol J

    更新日期:2020-06-01 00:00:00

  • Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.

    abstract::Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.49

    authors: Hirsch EB,Tam VH

    更新日期:2010-08-01 00:00:00

  • Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS.

    abstract::There have been great technological advances in the use of antiretroviral therapies to slow down disease progression in HIV/AIDS. Combinations of therapeutics and the use of several diagnostic methods have resulted in both declines in mortality and the occurrence of opportunistic infections. The higher costs of these ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.1.1.77

    authors: Bos JM,Berg LT,Postma MJ

    更新日期:2001-10-01 00:00:00

  • Towards a healthier discount procedure.

    abstract::Most national guidelines for pharmacoeconomic research prescribe discounting, mostly of money and health against the same rate. There is much debate on whether this is adequate. Two theoretical arguments, the consistency argument of Weinstein and Stason, and the paralyzing paradox of Keeler and Cretin, are mostly resp...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.1.59

    authors: Klock RM,Brouwer WB,Annemans LJ,Bos JM,Postma MJ

    更新日期:2005-02-01 00:00:00

  • Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain.

    abstract:AIM:Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS:A total of 60 respondents, recruited from the UK...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.48

    authors: Wild D,Murray M,Donatti C

    更新日期:2009-10-01 00:00:00

  • Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation.

    abstract::The primary objective of this review is to develop a conceptual model for Crohn's disease (CD) outlining the disease burden for patients, healthcare systems and wider society, as reported in the scientific literature. A search was conducted using MEDLINE, PsycINFO, EconLit, Health Economic Evaluation Database and Cent...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2015.1045883

    authors: Gater A,Kitchen H,Heron L,Pollard C,Håkan-Bloch J,Højbjerre L,Hansen BB,Strandberg-Larsen M

    更新日期:2015-01-01 00:00:00

  • Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.

    abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1800457

    authors: Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

    更新日期:2020-08-01 00:00:00

  • Antibiotics and reduced risk of COPD re-exacerbations.

    abstract::Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.33

    authors: Antoniu SA

    更新日期:2009-08-01 00:00:00

  • Probabilistic choice models in health-state valuation research: background, theories, assumptions and applications.

    abstract::Interest is rising in measuring subjective health outcomes, such as treatment outcomes that are not directly quantifiable (functional disability, symptoms, complaints, side effects and health-related quality of life). Health economists in particular have applied probabilistic choice models in the area of health evalua...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.12.85

    authors: Arons AM,Krabbe PF

    更新日期:2013-02-01 00:00:00

  • Cost analysis and clinical applicability of the Resonance metallic ureteral stent.

    abstract::The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.74

    authors: Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

    更新日期:2010-02-01 00:00:00

  • Better big data.

    abstract::By 2018, Medicare payments will be tied to quality of care. The Centers for Medicare and Medicaid Services currently use quality-based metric for some reimbursements through their different programs. Existing and future quality metrics will rely on risk adjustment to avoid unfairly punishing those who see the sickest,...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 社论

    doi:10.1586/14737167.2015.1083864

    authors: Al Kazzi ES,Hutfless S

    更新日期:2015-01-01 00:00:00

  • A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.

    abstract::Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2016.1135740

    authors: Márquez-Cruz M,Díaz-Martínez JP,Soto-Molina H,De Saráchaga AJ,Cervantes-Arriaga A,Llorens-Arenas R,Rodríguez-Violante M

    更新日期:2016-01-01 00:00:00

  • A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics.

    abstract::We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2013.838027

    authors: Neumann PJ,Saret CJ

    更新日期:2013-10-01 00:00:00

  • Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

    abstract:BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1476142

    authors: Grewal S,Ramsey S,Balu S,Carlson JJ

    更新日期:2018-08-01 00:00:00

  • Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.

    abstract:BACKGROUND:The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. AIM:To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. METH...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.1081061

    authors: Gimeno-Ballester V,Mar J,San Miguel R

    更新日期:2016-01-01 00:00:00

  • Cost of treating otitis media in Australia.

    abstract:OBJECTIVE:Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). METHODS:Little Australia-w...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.6

    authors: Taylor PS,Faeth I,Marks MK,Del Mar CB,Skull SA,Pezzullo ML,Havyatt SM,Coates HL

    更新日期:2009-04-01 00:00:00

  • The cost-effectiveness of therapies to treat alcohol use disorders.

    abstract:INTRODUCTION:Alcohol use is a major risk factor for mortality and morbidity burden, and alcohol use disorders contribute markedly to this burden. Effective interventions for alcohol use disorders improve health, and are potentially cost-effective or even cost saving. AREAS COVERED:We searched the literature for the co...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2018.1392241

    authors: Rehm J,Barbosa C

    更新日期:2018-02-01 00:00:00